| Drug Report: DETROL LA (TOLTERODINE TARTRATE) | ||||||||
| Primary Suspect Reports: 10,602 Total Reports: 18,250 FDA AERS Reports from 11/01/1997 to 08/27/2012 | ||||||||
| Drug Description : | ||||||||
Detrol LA (tolterodine tartrate extended-release capsules) is used to manage the symptoms of overactive bladder (OAB), such as leaks, sudden urges to urinate, and frequency. It is a once-daily capsule that helps calm bladder muscle for up to 24 hours. Detrol LA was FDA approved on December 22, 2000 and is manufactured by Amgen. |
||||||||
| Drug Safety Monitor News : | ||||||||
08/03/2012 - Pfizer Announces Toviaz More Effective than Detrol LA in Treating Overactive Bladder |
||||||||
| Other Names : | Generic Name : | Report Info: | ||||||
Tolterodine Tartrate |
TOLTERODINE TARTRATE | Average Age: 66 Years |
||||||
FDA Listed Names (286) :
|
Manufacturer: | Common Conditions: | ||||||
(detrusitol /01350202/) |
Pharmacia & Upjohn, Inc. (7,333) |
|
||||||
| Top DETROL LA Adverse Events/Side Effects |
|
|
|
| Side Effects MedDRA Preferred Terms |
DETROL LA Primary Suspect Reports | DETROL LA Total Reports |
ROR Score
|
PRR Score
|
Compare Top Drugs |
| Drug Ineffective | 2,004 (19%) | 2,435 (13%) | Premium Feature | Premium Feature |
 |
| Dry Mouth | 1,943 (18%) | 2,086 (11%) | Premium Feature | Premium Feature |
|
| Constipation | 784 (7%) | 1,024 (6%) | Premium Feature | Premium Feature |
|
| Headache | 673 (6%) | 1,079 (6%) | Premium Feature | Premium Feature |
|
| Dizziness | 602 (6%) | 1,089 (6%) | Premium Feature | Premium Feature |
|
| Urinary Incontinence | 580 (5%) | 751 (4%) | Premium Feature | Premium Feature |
|
| Pollakiuria | 485 (5%) | 609 (3%) | Premium Feature | Premium Feature |
|
| Dry Eye | 402 (4%) | 429 (2%) | Premium Feature | Premium Feature |
|
| Condition Aggravated | 387 (4%) | 676 (4%) | Premium Feature | Premium Feature |
|
| Oedema Peripheral | 377 (4%) | 679 (4%) | Premium Feature | Premium Feature |
|
|
Data downloads, Grouping Adverse Events by different MedDRA levels and PRR/ROR calculations are reserved for our Premium Subscribers.
Click here to learn more about subscription levels and pricing. Click here to view a sample report that includes the premium sections. |
|||||
| Reported Report Outcomes for DETROL LA Adverse Events |
| Report Outcomes |
DETROL LA Primary Suspect (# of Reports) (11/01/1997 to 08/27/2012) |
DETROL LA Total (# of Reports) (11/01/1997 to 08/27/2012) |
| Other | 2,727 (26%) | 5,457 (30%) |
| Hospitalization - Initial or Prolonged | 804 (8%) | 3,891 (21%) |
| Death | 163 (2%) | 757 (4%) |
| Disability | 140 (1%) | 459 (3%) |
| Life-Threatening | 61 (1%) | 413 (2%) |
| Required Intervention to Prevent Permanent Impairment/Damage | 41 (0%) | 236 (1%) |
| Congenital Anomaly | 9 (0%) | 15 (0%) |
| Most Recent DETROL LA Report Reviews/FDA Reports (Primary Suspect) |
| Report Date | Age | Gender | Conditions | Adverse Events | Outcome |
| 08/27/2012 | Not Stated | F |
Hypertonic Bladder |
Drug Ineffective |
Not Stated |
| 08/23/2012 | 85 YR | F |
Angina Pectoris Blood Cholesterol Increased Drug Therapy Show All |
Dry Mouth Incorrect Dose Administered |
Not Stated |
| 08/22/2012 | Not Stated | F |
Urinary Incontinence |
Drug Ineffective |
Not Stated |
| 08/22/2012 | 61 YR | F |
Bladder Disorder Diabetes Mellitus Diuretic Therapy Show All |
Chondropathy |
Hospitalization - Initial or Prolonged |
| 08/20/2012 | 55 YR | F |
Nerve Injury Urinary Incontinence |
Drug Ineffective Insomnia |
Not Stated |
| 08/20/2012 | 87 YR | F |
Urinary Incontinence |
Urinary Incontinence Urinary Tract Infection Amnesia Show All |
Other |
| 08/20/2012 | 25 YR | F |
Contraception Hypertonic Bladder |
Thirst Malaise Migraine Show All |
Other |
| 08/17/2012 | 75 YR | M |
Hypertonic Bladder |
Interstitial Lung Disease |
Other |
| 08/16/2012 | Not Stated | F |
Urinary Incontinence |
Drug Ineffective |
Not Stated |
| 08/15/2012 | 51 YR | F |
Hypertension Hypertonic Bladder |
Arthritis |
Disability |
